Moderna Stock Financials

MRNA -  USA Stock  

USD 132.06  5.56  4.04%

Understanding current and past Moderna Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Moderna's financial statements are interrelated, with each one affecting the others. For example, an increase in Moderna's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Moderna's financials over time to get the whole picture.
The current year Average Assets is expected to grow to about 20.1 B. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 14.6 B.
We recommend to make use of Moderna fundamental analysis to see if markets are presently mispricing the entity. Strictly speaking, this technique allows you to check out available financial ratios of Moderna as well as the relationship between them. We were able to interpolate thirty-five available fundamentals for Moderna, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Moderna financials, including its price to sales, cash per share, and the relationship between the number of shares shorted and ebitda . Given that Moderna has a number of shares shorted of 15.43 M, we recommend you to check Moderna last-minute market performance to make sure the company can sustain itself down the road. Use Moderna to protect your portfolios against small market fluctuations. The stock experiences a very speculative upward sentiment. Check odds of Moderna to be traded at $125.46 in 90 days.
With this module, you can analyze Moderna financials for your investing period. You should be able to track the changes in Moderna individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Moderna is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Moderna includes many different criteria found on its balance sheet. For example, investors should never minimize Moderna's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Moderna's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Moderna.

Moderna Cash

Chance Of Financial Distress
Less than 34
Moderna has less than 34 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Moderna stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Moderna's official financial statements usually reflect Moderna's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moderna. For example, before you start analyzing numbers published by Moderna accountants, it's critical to develop an understanding of what Moderna's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moderna's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moderna. Please utilize our Beneish M Score to check the likelihood of Moderna's management to manipulate its earnings.

Moderna Company Summary

Moderna competes with Brickell Biotech, and Berkeley Lights. Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.
Foreign Associate  Mexico
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
LocationMassachusetts; U.S.A
Business Address200 Technology Square
Phone617 714 6500
Related EntityMRNA
CurrencyUSD - US Dollar
You should never invest in Moderna without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Moderna Stock, because this is throwing your money away. Analyzing the key information contained in Moderna's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Moderna Key Financial Ratios

Generally speaking, Moderna's financial ratios allow both analysts and investors to convert raw data from Moderna's financial statements into concise, actionable information that can be used to evaluate the performance of Moderna over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Moderna reports annually and quarterly.

Moderna Key Balance Sheet Accounts

201720182019202020212022 (projected)
Total Assets1.08 B1.96 B1.59 B7.34 B24.67 B26.62 B
Current Assets783.22 M1.56 B1.13 B6.3 B16.07 B17.34 B
Assets Non Current301.27 M399.14 M460.62 M1.04 B8.6 B9.28 B
Cash and Equivalents135.81 M658.96 M236.91 M2.62 B6.85 B7.39 B
Total Debt15.69 M33.49 M132.36 M207 M705 M760.66 M
Debt Non Current15.69 M33.49 M132.36 M207 M705 M760.66 M
Deferred Revenue339.67 M274.41 M202.31 M4.04 B6.87 B7.41 B
Shareholders Equity(551.37 M)1.53 B1.17 B2.56 B14.14 B15.26 B
Investments778.82 M1.05 B1.04 B2.63 B10.73 B11.58 B
Investments Current621.17 M863.06 M867.12 M1.98 B3.88 B4.19 B
Total Liabilities459.19 M431.91 M414.61 M4.78 B10.52 B11.35 B
Current Liabilities191.46 M222.8 M143.12 M4.39 B9.13 B9.85 B

Moderna Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Moderna's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(255.92 M)(384.73 M)(514 M)(747 M)12.2 B13.17 B
Gross Profit205.82 M135.07 M60 M795 M15.85 B17.11 B
Net Income(255.92 M)(384.73 M)(514 M)(747 M)12.2 B13.17 B
Operating Expenses475.18 M548.33 M606 M1.56 B2.56 B2.76 B
Operating Income(269.36 M)(413.27 M)(546 M)(763 M)13.3 B14.35 B
Revenues205.82 M135.07 M60 M803 M18.47 B19.93 B
Income Tax Expense(80 K)326 K(1,000 K)3 M1.08 B1.17 B

Moderna Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Moderna. It measures of how well Moderna is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Moderna brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Moderna had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Moderna has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(58.4 M)(105.77 M)(32 M)(68 M)(284 M)(291.47 M)
Depreciation Amortization and Accretion20.54 M24.86 M31 M93 M232 M250.32 M
Net Cash Flow or Change in Cash and Cash Equivalents86.05 M522.88 M(422 M)2.39 B4.22 B4.56 B
Issuance Purchase of Equity Shares212 K564.45 M51 M2.04 B(733 M)(752.29 M)
Net Cash Flow from Financing168 K1.23 B52 M2.03 B(873 M)(895.97 M)
Net Cash Flow from Investing417.36 M(373.09 M)(15 M)(1.67 B)(8.52 B)(8.75 B)
Net Cash Flow Investment Acquisitions and Disposals475.76 M(267.33 M)17 M(1.6 B)(8.24 B)(8.46 B)
Net Cash Flow from Operations(331.48 M)(330.87 M)(459 M)2.03 B13.62 B14.7 B
Share Based Compensation40.05 M72.56 M81 M93 M142 M119.89 M

Moderna Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Moderna's current stock value. Our valuation model uses many indicators to compare Moderna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moderna competition to find correlations between indicators driving Moderna's intrinsic value. More Info.
Moderna is regarded second in debt to equity category among related companies. It is regarded second in total asset category among related companies fabricating about  118,671,875  of Total Asset per Debt to Equity. The current year Total Assets is expected to grow to about 26.6 B. The current year Average Assets is expected to grow to about 20.1 B. Comparative valuation analysis is a catch-all model that can be used if you cannot value Moderna by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Moderna's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moderna's earnings, one of the primary drivers of an investment's value.

Moderna Systematic Risk

Moderna's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Moderna volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Moderna correlated with the market. If Beta is less than 0 Moderna generally moves in the opposite direction as compared to the market. If Moderna Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Moderna is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Moderna is generally in the same direction as the market. If Beta > 1 Moderna moves generally in the same direction as, but more than the movement of the benchmark.

About Moderna Financials

What exactly are Moderna Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Moderna's income statement, its balance sheet, and the statement of cash flows. Potential Moderna investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Moderna is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Moderna grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Moderna Thematic Clasifications

Moderna is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
Biotech Idea
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas

Moderna May 24, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Moderna help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Moderna. We use our internally-developed statistical techniques to arrive at the intrinsic value of Moderna based on widely used predictive technical indicators. In general, we focus on analyzing Moderna Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Moderna's daily price indicators and compare them against related drivers.
Downside Deviation4.03
Information Ratio0.026
Maximum Drawdown23.51
Value At Risk(6.72)
Potential Upside8.59
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.